NOXXON Receives Grant For Human Clinical Trial With Spiegelmer NOX-A12

NOXXON Pharma has received a research grant from Germany’s Federal Ministry of Education and Research (BMBF), under the Ministry’s small-and-medium-enterprise innovation initiative (KMU-Innovativ).

The grant was presented to NOXXON following the completion of a peer reviewed selection process. Under the initiative, NOXXON will receive E1.2m in funding for the impending phase I clinical development of its candidate – Spiegelmer NOX-A12. The company develops NOX-A12 for use in autologous hematopoietic stem cell transplantation in patients suffering from non-Hodgkin’s lymphoma or multiple myeloma.

Frank Morich, chief executive officer of NOXXON, said: “In awarding this competitive research grant to NOXXON, the BMBF acknowledges our tremendous progress in maturing Spiegelmer compounds into therapeutic candidates for human use. The transition from pre-clinical studies to clinical trials is a critical junction in the development of an innovative compound. We are grateful to the BMBF for providing grant support at this crucial stage.”